2024.09.27
PROFESSOR WANG YANS TEAM AT XIAMEN UNIVE···
On September 24, 2024, led by President Wang Yan
of Xiamen University Affiliated Cardiovascular
Ho···
2024.09.24
REGISTERED CLINICAL DATA OF TaurusElite®···
During September 20-22, 2024, Peijia presented multiple
clinical data at the PCR-CIT China Chengdu ···
2024.08.15
PEIJIA MEDICAL RECEIVES THE NMPA APPROVA···
Peijia Medical received the NMPA approval for the registration application of TaurusMax™ in August 1···
2024.06.13
HighLife® Transseptal Mitral Valve Repla···
From June 5 to 7, 2024, the New York Valves (NYV) conference was held, where Prof. Nicolo Piazza of ···
2024.06.13
MonarQ™ Transcatheter Tricuspid Valve Re···
From June 5 to 7, 2024, the latest results of the FIM clinical implantation of MonarQTM, an innovati···
2024.04.22
PEIJIA MEDICAL SHONE AT TWO MAJOR STRUC···
On March 18-24 and April 15-20, 2024, Peijia Medical shone at the 5th China Structural Heart Disease···
2024.04.19
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S···
On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by ···
2024.04.15
INNOVATIVE TRANSCATHETER EDGETO-EDGE RE···
On April 12, 2024, the results of GeminiOne® for DMR were published in JACC: Case Reports, a leading···
2024.03.29
Trilogy™ THV SYSTEM FOR AR INDICATION: R···
On March 26, 2024, the exciting results of JenaValve TrilogyTM System’s pivotal clinical trial, ALIG···
2024.03.01
TaurusNXT® NON-GLUTARALDEHYDE CROSSLINKE···
In February 2024, TaurusNXT® Non-glutaraldehyde Crosslinked dry-tissue TAVR system, a thirdgenerati···
2024.02.01
TaurusAtlas Pro, THE SECOND-GENERATION B···
The registration application of TaurusAtlas Pro, the second-generation balloon dilatation catheter i···
2024.01.29
TaurusTrio AR TAVR SYSTEM COMPLETED ALL ···
In January 2024, TaurusTrio AR TAVR System successfully completed patient enrollment in its mu···
